Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Other Accumulated Expenses (2017 - 2023)

Historic Other Accumulated Expenses for Vistagen Therapeutics (VTGN) over the last 7 years, with Q2 2023 value amounting to $10000.0.

  • Vistagen Therapeutics' Other Accumulated Expenses rose 8518.52% to $10000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $10000.0, marking a year-over-year increase of 8518.52%. This contributed to the annual value of $32700.0 for FY2022, which is 1762.59% up from last year.
  • Per Vistagen Therapeutics' latest filing, its Other Accumulated Expenses stood at $10000.0 for Q2 2023, which was up 8518.52% from $1200.0 recorded in Q3 2022.
  • Over the past 5 years, Vistagen Therapeutics' Other Accumulated Expenses peaked at $62600.0 during Q3 2021, and registered a low of $1200.0 during Q3 2022.
  • In the last 5 years, Vistagen Therapeutics' Other Accumulated Expenses had a median value of $13200.0 in 2020 and averaged $18383.3.
  • Per our database at Business Quant, Vistagen Therapeutics' Other Accumulated Expenses surged by 28170.73% in 2021 and then plummeted by 9808.31% in 2022.
  • Quarter analysis of 5 years shows Vistagen Therapeutics' Other Accumulated Expenses stood at $7900.0 in 2019, then tumbled by 30.38% to $5500.0 in 2020, then soared by 1038.18% to $62600.0 in 2021, then tumbled by 98.08% to $1200.0 in 2022, then surged by 733.33% to $10000.0 in 2023.
  • Its Other Accumulated Expenses was $10000.0 in Q2 2023, compared to $1200.0 in Q3 2022 and $5400.0 in Q2 2022.